Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma

Jun Liu; Yang Yang; Zhichao Liu; Xiaolong Fu; Xiaoyue Cai; Hongxuan Li; Li Zhu; Yan Shen; Hong Zhang; Yifeng Sun; Hezhong Chen; Bentong Yu; Renquan Zhang; Jinchen Shao; Ming Zhang; Zhigang Li

doi:10.1136/jitc-2021-004291

March 1, 2022SHILAP Revista de lepidopterologíaOpen Access

Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma

View Full Paper

Ask AI

Bookmark

Share

Key Points

To assess the efficacy and safety of camrelizumab combined with chemotherapy as a neoadjuvant intervention in patients with locally advanced esophageal squamous cell carcinoma.
Conducted a multicenter, single-arm, phase II clinical trial (ChiCTR1900026240).
Administered neoadjuvant camrelizumab in combination with chemotherapy prior to surgical resection in patients with locally advanced esophageal squamous cell carcinoma.
The clinical trial is registered under identifier ChiCTR1900026240 to investigate preoperative treatment response and resectability.

No abstract yet

We only have this paper's title and publication details.

Read it at the source

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Phase II trial reports neoadjuvant camrelizumab plus chemotherapy in locally advanced esophageal squamous cell carcinoma, highlighting feasibility for preoperative management.

Abstract

ChiCTR1900026240.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Liu et al. (2022) studied this question.

synapsesocial.com/papers/69dd5d92629747396240c5b7 https://doi.org/10.1136/jitc-2021-004291

View Full Paper

Ask AI

Bookmark

Share

Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma

Key Points

No abstract yet

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma

Key Points

No abstract yet

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading